Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Evolocumab (Repatha) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Alirocumab (Praluent) and Evolocumab (Repatha) have evidence — compare verdict strength side-by-side.
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
any
Subcutaneous prefilled pen/syringe (alirocumab)
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
any
Subcutaneous prefilled autoinjector (evolocumab)
Within weeks
Months to years
Years
At each injection
Weeks
Months to years
Weeks
Throughout use
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
The New England journal of medicine (2017) · Rct · n=27564
FOURIER randomized ~27,564 patients with atherosclerotic cardiovascular disease on statin therapy
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation (2022) · Open label
FOURIER-OLE: open-label extension following patients on long-term evolocumab
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA (2016) · Rct
GLAGOV randomized statin-treated patients to evolocumab or placebo with serial intravascular ultrasound
Evolocumab (Repatha) has a higher evidence score (4.5/10 vs 4.5/10) and wins in 2 of 3 categories.
No known interactions between Alirocumab (Praluent) and Evolocumab (Repatha) have been documented in our database. However, always consult a healthcare provider before combining supplements.